News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Merck & Co.
NEWS
JOBS
IN THE PRESS
AWARDS
NEWS
Takeda Pharmaceutical Co. Ltd.(Jobs), Eisai Company, Ltd. Takeovers Raise Biotech Costs for Merck & Co., Inc.(Jobs), Novartis International AG(Jobs)
April 19, 2007
·
1 min read
Biotech Beach
The Day In Review: Dyax Corp. Jumps On Positive Data
April 13, 2007
·
1 min read
Biotech Beach
The Day In Review: MedImmune, Inc. Puts Itself Up For Sale
April 13, 2007
·
1 min read
Biotech Bay
The Day In Review: Roche Picks Up Antibody Firm For $56.5 Million
April 2, 2007
·
1 min read
Biotech Beach
The Day In Review: Biosite Incorporated Takes $85 Offer From Beckman Coulter, Inc.
March 26, 2007
·
1 min read
The Day In Review: Eisai Inc. Buys Morphotek Inc. For $325 Million
March 22, 2007
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
February 26, 2026
·
8 min read
Press Releases
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
February 26, 2026
·
19 min read
Press Releases
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 24, 2026
·
8 min read
Press Releases
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
·
3 min read
Press Releases
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
February 23, 2026
·
5 min read
Press Releases
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
February 19, 2026
·
12 min read
Press Releases
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
February 18, 2026
·
5 min read
Press Releases
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications
February 17, 2026
·
7 min read
Press Releases
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
February 12, 2026
·
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
February 11, 2026
·
19 min read
